Patients with pSS exhibit increased IL-17 production from CD161+ T cell subsets, with elevated frequencies of CD4+CD161+ T cells and their effector populations showing positive correlation with both disease activity indices and clinical severity, suggesting their pathogenic involvement and potential as therapeutic targets in pSS (47). The gene discussed is CD4; the disease is peeling skin syndrome.